Stool Log Get the app

Tracking constipation on a GLP-1 medicine

Constipation, nausea and diarrhoea are listed among the common side effects of GLP-1 medicines such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). A short diary shows your prescriber what is happening, and when.

Why a diary helps on these medicines

Constipation, diarrhoea, nausea and vomiting are among the most common side effects in the labels of these medicines.12 They reduce your appetite and slow digestion, and both can change your bowel habits.3 In trials of tirzepatide (Zepbound), most nausea, vomiting and diarrhoea came while the dose was being raised, and eased over time.4

That makes timing the useful part. "I've been constipated" is hard to act on. "Since my dose went up three weeks ago I've gone twice a week, mostly type 1 and 2" gives your prescriber something to work with.

What to log

Keep it to a few things you can note in seconds:

Reading your own pattern

After two or three weeks, look for:

You're not looking for a cause on your own. You're collecting what your prescriber will ask about.

Talking to your prescriber

Bring your weekly numbers and the dates of any dose change. Ask what they'd like you to do if constipation continues, and whether any laxative or supplement is right for you. Don't change, skip or stop doses on your own: talk to your prescriber first.3

The labels also list rare reports of a blocked bowel and severe constipation since these medicines came on the market.1 Mention any big change in how you go.

Keeping it easy

A once-a-week injection is easy to forget to write down, and so is water. A reminder on your dose day and a quick note after each stool are enough. If you'd rather use paper, our printable stool diary has room for a week.

Note each dose, then log each stool, then bring the report.

Sources

  1. US Food and Drug Administration (via DailyMed). Wegovy (semaglutide) prescribing information, 2026. ↩ a b c
  2. NHS. Tirzepatide: a medicine to manage type 2 diabetes and treat obesity, 2026. ↩ a b
  3. NHS. Semaglutide: a medicine to manage type 2 diabetes or treat obesity, 2026. ↩ a b
  4. US Food and Drug Administration (via DailyMed). Zepbound (tirzepatide) prescribing information, 2026. ↩
  5. NHS. Dehydration, 2026. ↩ a b
  6. NHS. Constipation, 2023. ↩ a b

This article is general information, not medical advice. Talk to a doctor or nurse about your own symptoms.